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Carnosol controls the human 
glioblastoma stemness 
features through the epithelial-
mesenchymal transition 
modulation and the induction of 
cancer stem cell apoptosis
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Alessandra Braca1,2, M. Letizia Trincavelli  1,2 & Claudia Martini1,2
A high cell proliferation rate, invasiveness and resistance to chemotherapy are the main features of 
glioblastoma (GBM). GBM aggressiveness has been widely associated both with a minor population of 
cells presenting stem-like properties (cancer stem-like cells, CSCs) and with the ability of tumor cells 
to acquire a mesenchymal phenotype (epithelial-mesenchymal transition, EMT). Carnosol (CAR), a 
natural inhibitor of MDM2/p53 complex, has been attracted attention for its anti-cancer effects on 
several tumor types, including GBM. Herein, the effects of CAR on U87MG-derived CSC viability and 
stemness features were evaluated. CAR decreased the rate of CSC formation and promoted the CSC 
apoptotic cell death through p53 functional reactivation. Moreover, CAR was able to control the TNF-α/
TGF-β-induced EMT, counteracting the effects of the cytokine on EMT master regulator genes (Slug, 
Snail, Twist and ZEB1) and modulating the activation of miR-200c, a key player in the EMT process. 
Finally, CAR was able to increase the temozolomide (TMZ) anti-proliferative effects. These findings 
demonstrate that CAR affected the different intracellular mechanism of the complex machinery that 
regulates GBM stemness. For the first time, the diterpene was highlighted as a promising lead for the 
development of agents able to decrease the stemness features, thus controlling GBM aggressiveness.
Glioblastoma multiforme (GBM) is the most aggressive form of glioma (WHO grade IV) and displays strong 
infiltrating properties1. The first therapeutic choice is surgery, followed by the treatment with the alkylating agent, 
Temozolomide (TMZ). Nevertheless, the median survival of patients with GBM is only 2 years after diagnosis, 
due to the resistance to therapy and/or tumor recurrence2,3. The aggressive phenotype4, the invasiveness and the 
resistance to chemotherapy and radiotherapy5,6 of GBM have been correlated with the expression of stem cell 
markers7,8 and with the acquisition of a mesenchymal phenotype9–11. The tumor bulk contributing to the stemness 
of GBM includes cancer stem cells (CSCs) and cells with a mesenchymal phenotype, which are derived from the 
de-differentiation of cells with an epithelial phenotype. In this light, great interest in the discovery of novel thera-
peutic approaches that are able to target cancer cells with a stem phenotype has arisen.
The epithelial-mesenchymal transition, commonly known as the EMT, is an evolutionary process in which 
cells lose their epithelial features and acquire a mesenchymal phenotype through concerted and tightly regulated 
epigenetic and biochemical processes12,13. The EMT is indispensable in physiological processes such as wound 
healing and embryonic development. Conversely, in the cancer bulk, the induction of the EMT has been linked 
to the acquisition of a more stem-like phenotype14, which confers resistance to therapy, aggressive traits and an 
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invasive phenotype to cells. The EMT have been widely implicated in the aggressiveness of different solid tum-
ors15, including GBM16–19, and has been linked to frequent tumor recurrence and metastasis.
The GBM malignancy is also increased by the presence of a sub-population of cancer cells with extremely high 
tumorigenic potential: the CSCs. In the last decade, these cells have been isolated from a variety of cancers20–23, 
including GBM24–28. CSCs present properties of self-renewal, multipotent differentiation and the capacity to gen-
erate new tumors with the same heterogeneity as the original tumors. These cells contribute to the aggressiveness, 
frequent relapse and higher resistance to chemotherapy and radiotherapy of GBM8.
Several studies have identified correlations between the EMT and CSCs. Generally, CSCs are proposed to orig-
inate either from adult stem cells that have undergone a malignant change, or from differentiated cells (progenitor 
cells) that have acquired the ability to self-renew and de-differentiate into cancer cells with more stem-like prop-
erties29–31. Cancer cells that underwent the EMT exhibit a CSC-like phenotype, acquiring a greater stemness pro-
file32–34. Although the exact link between the CSC-EMT and tumor progression is not clear, the discovery of novel 
agents that are able to eradicate these subpopulations of cells with stem-like properties has arisen as an important 
challenge in the development of effective GBM treatments. In the last years, several strategies have been pursued 
to target CSCs, such as induction of apoptosis, inhibition of self-renewal and chemoresistance-related pathways, 
or induction of their differentiation35.
In this scenario, phytochemicals have been shown to be promising as anti-cancer treatments, contributing to 
both the modulation of the EMT and the reduction of CSC viability36–41. Among the various phytochemicals with 
anticancer properties, the diterpene carnosol (CAR) has shown to have significant cytotoxic effects on several 
human cancer cell lines and animal models42,43. CAR is a naturally occurring phenolic diterpene found in several 
Mediterranean herbs and is a major component of rosemary (Rosmarinus officinalis L.)42,43. In a our recent study, 
CAR exerted an anti-proliferative effect on GBM through the inhibition of the MDM2/p53 complex and the 
functional reactivation of the p53 pathway44. Vergara et al. reported the ability of the diterpene to inhibit the EMT 
in ovarian cancer43. However, to the best of our knowledge, no data have been reported on the effects of CAR on 
CSCs and the EMT in glioma.
Herein, for the first time, the ability of CAR to modulate the EMT and affect the CSCs viability were evaluated 
in human GBM cell model. CAR decreased the expression of transcription factors implicated in the induction of 
the EMT, thus preventing the transition. Furthermore, CAR controlled the EMT transition affecting the expres-
sion of the intracellular small non-coding RNA miR-200c, which is a key regulator of the EMT and promotes 
the expression of stemness-related genes in CSCs45–47. Moreover, CAR promoted the CSC death increasing the 
effect of TMZ. The diterpene was also able to control the self-renewal of the CSCs by inhibiting the expression of 
stemness-related genes (nanog, SOX2 and Oct4) CAR could represent a tool to better understand the mechanism 
that confers the highly aggressiveness to the brain tumors. Furthermore, the diterpene could represent the start-
ing point for the development of more effective chemotherapeutic agents able not only to control the proliferation 
of the differentiated cells but also to affect the CSCs pool increasing their sensitivity to TMZ treatment.
Results
Experimental plan. As a representative GBM cell line, we used U87MG cells, which is an appropriate model 
to study the effects of the MDM2-p53 complex inhibitor CAR. In fact, the U87MG cells maintain a wild type 
status of p53, and are deficient for the tumour suppressor phosphatase and tensin homologue (PTEN) that leads 
to MDM2 nuclear accumulation, thus inhibiting p53 functions48.
CAR treatment decreases adherent U87MG cell proliferation with an IC50 values of 28.9 µM and 14.9 µM after 
24 h or 48 h, respectively, due to the p53 reactivation44. P53 could affect other features of cancer cells, thus, in 
order to assess the CAR effects in adherent U87MG, a concentration lower than the anti-proliferative IC50 values 
was used.
Then, the CAR cellular activity and molecular mechanisms were explored in different human GBM derived 
stem cells (CSCs) expressing wild-type p53 (U87MG and U343MG) or mutated p53 (T98G)48.
Effects of CAR on EMT process in GBM cells. Induction of the EMT in U87MG cells through inflamma-
tory priming. Cytokines released in the tumor microenvironment are known to affect the phenotype of the 
cancer cells, leading to the acquisition of a higher stem grade49. Moreover, they could affect the cancer stem cell 
pool, prompting the maintenance of greater stem-like features. Typically, the EMT process is initiated by the 
action of different cytokines and extracellular stimuli50. Therefore, U87MG cells were induced to undergo the 
EMT by treatment with a mixture of the cytokines TNF-α (10 ng/ml) and TGF-β1 (10 ng/ml) for 48 h. First, a 
morphological analysis of the cells was performed (Fig. 1A). The TNF-α/TGF-β1 treatment induced a change 
in cell morphology: U87MG cells, which normally display an oval shape, showed an elongated shape with a 
fibroblast-like appearance.
The morphological changes, which are characteristic of cells undergoing the EMT, are accompanied by a shift 
in the expression from epithelial genes to a mesenchymal gene repertoire19,50. Accordingly, challenging cells with 
the TNF-α/TGF-β1 mixture modified the expression of EMT markers, leading to a significant increase in the 
expression of the mesenchymal marker and a concomitant decrease in the expression of the epithelial marker 
E-cadherin (2.77 ± 0.69- and 0.69 ± 0.08-fold vs. CTRL, respectively; Fig. 1B). The data were confirmed at the 
protein level by Western blots for N- and E-cadherin (Fig. 1C,D).
The EMT is regulated by the activity of four main master regulator transcription factors (TFs): Snail, Slug, 
Twist and ZEB119,50. Herein, the TNF-α/TGF-β1 treatment did not significantly affect the expression of the Snail 
gene. Conversely, the cytokine mixture significantly increased the expression of the other TFs, as compared to the 
control cells (Fig. 1E). Taken together, the data highlighted the ability of the inflammatory microenvironment to 
induce the EMT in U87MG cells.
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Figure 1. CAR modulation on the TNF-α/TGF-β1-induced EMT. U87MG cells were treated with TNF-α 
(10 ng/ml)/TGF-β1 (10 ng/ml) in the absence or the presence of CAR (10 µM) in complete medium for 48 h. 
(A) At the end of the incubation, representative images were taken. (B) Real Time RT-PCR analysis of the EMT 
markers. The data were the mean values from three different experiments. (C,D) U87MG cells were treated as 
described above, and the levels of the EMT markers were evaluated by Western blotting with the use of specific 
antibodies. One representative Western blot is presented (C). The bar graph (D) shows the densitometric 
analysis of the Western blot, which was performed using the ImageJ program. The data are presented as the 
means of three different experiments. (E) Real Time RT-PCR analysis of the transcription factors that act as 
master regulators of the EMT (Snail, Slug, Twist and ZEB1) (F) U87MG cells were treated as indicated, and 
the levels of miR-200c were quantified at the end of the incubation. The data are presented as the means of 
three different experiments each performed in duplicate. The significance of the differences was determined by 
one-way ANOVA, followed by Bonferroni’s post hoc test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs. the control; 
#P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001 vs. TNF-α/TGF-β1 alone; §§P ≤ 0.01, §§§P ≤ 0.001 vs. CAR alone.
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CAR modulates the induced EMT in U87MG cells. In the literature, there are no reports on the effect of the rose-
mary component on the EMT. Thus, the effects of CAR in U87MG human glioblastoma cell induced-EMT were 
investigated. The cells treated with CAR (10 µM) exhibited a change in the expression of surface EMT markers. 
In particular, treatment with the diterpene alone significantly increased both the expression of the E-cadherin 
both at mRNA and protein level, with a simultaneous slight decrease in N-cadherin expression (Fig. 1B–D). 
CAR interfered with the EMT, even if the effect was not sufficient to modulate the profile of the EMT master 
regulators that are tightly controlled by several feed-back mechanisms. Furthermore, CAR induced a significant 
change in the expression of epithelial and mesenchymal markers, at the mRNA (N-cad 2.0 ± 0.1, P ≤ 0.05 and 
E-cad 1.5 ± 0.3 P ≤ 0.01 vs. TNF-α/TGF-β1 treatment) and protein levels (N-cad 68.4 ± 12.4, P ≤ 0.001 and E-cad 
73.5 ± 7.3 P ≤ 0.05 vs. TNF-α/TGF-β1 treatment). These data agreed with the morphological changes observed 
in the cells after the CAR treatment (Fig. 1A). Thus, CAR negatively regulated the TNF-α/TGF-β1-induced EMT, 
resulting in the maintenance of a reduced mesenchymal phenotype of the human U87MG cells.
CAR modulated the genes regulating the cytokine-induced EMT in adherent U87MG cells. CAR alone did not 
significantly modulate the expression of the TFs Snail, Slug, Twist and ZEB1, which have been identified as master 
regulators of the EMT. However, CAR counteracted the up-regulation of Slug, Twist and ZEB1 induced by the 
cytokine mixture (Fig. 1E).
Among the different regulatory pathways involved in the EMT, the expression of specific miRNAs has 
attracted substantial interest. miR-200c is a key negative regulator of the EMT51. Thus, the intracellular expression 
of miR-200c was evaluated in response to TNF-α/TGF-β1 stimuli in the absence or presence of CAR (Fig. 1F). As 
expected, the TNF-α/TGF-β1 mixture induced a significant decrease in miR-200c expression (0.04 ± 0.01-fold 
vs. CTRL, P ≤ 0.001). CAR significantly counteracted the effect of the cytokine mix (0.16 ± 0.02-fold vs. TNF-α/
TGF-β1), even if it was not able to completely restore the control profile. The analysis of the correlation with the 
expression of the EMT markers indicated that the epigenetic control of miR-200c could be one of the mechanisms 
underlying the inhibitory effects of CAR on GBM cell mesenchymal transformation. Notably, CAR did not affect 
miRNA expression in the absence of the cytokine mixture.
Effects of CAR on CSC biological properties. The stem-like features of U87MG cells are influenced by 
the CAR treatment. U87MG cells, as well as other GBM cells, are heterogeneous and normally include a small 
fraction of CSCs52. The expression of stem cell markers was evaluated to assess the effect of CAR on the stem-like 
nature of the differentiated cancer cell line (Fig. 2A). CAR significantly decreased the expression of the stemness 
genes CD44, Nanog, Oct4, BMI1 and SOX2, when it was used at a 10 µM concentration, demonstrating that the 
diterpene affected the stemness of the CSC fraction that is normally present in culture lines.
Then, the ability of CAR to affect the process by which glioblastoma CSCs are formed was examined. For this 
purpose, adherent U87MG cells were switched to a serum-free NSC medium and the cells were allowed to growth 
for additional 9 days in the presence or absence of different concentration of CAR (10 nM–20 µM) (Fig. 2B–D). 
CAR was able to reduce the number of spheres in a dose-dependent manner, indicating its capacity to alter the 
process by which stem cells are generated within tumor bulk (Fig. 2C). Furthermore, CAR decreased the diam-
eter of the newly formed spheres suggesting the compound’s ability to inhibit the proliferation of glioblastoma 
stem cells (Fig. 2D). The CAR concentration used here was ten times lower than the IC50 value reported for the 
anti-proliferative activity44 to discriminate the apoptotic effect on U87MG cells and the real inhibitory effect on 
CSC formation.
In order to confirm the CAR inhibitory effects on CSC formation, the expression of stem cell (CD44, Nanog, 
Nestin and OLIG2) and differentiated cell (GFAP) marker genes were evaluated. CAR significantly decreased the 
mRNA expression of stem cell markers and increased the expression of the GFAP mRNA (Fig. 2E), thus demon-
strating its ability to modulate the de-differentiation of GBM cancer cells.
CAR decreased CSC viability and promoted TMZ-induced anti-proliferative effects. Based on the role of the CSC 
subpopulation in GBM invasiveness and recurrence, we examined the effects of CAR on pre-formed glioblastoma 
derived-CSCs. The formation of neurospheres in U87MG, U343MG and T98G cell cultures in vitro was induced 
by a specific neural stem-cell (NSC) medium53,54. Consistent with literature data53–56, the spheres obtained using 
U87MG, U343MG and T98G (Fig. S1, Figs 2 and 3) included significantly higher levels of the stem cell markers 
CD133, Nanog, Nestin, OLIG2, CD44, SOX2, Oct4, BMI1 and STAT3 a smaller percentage of GFAP compared 
with the adherent counterpart (Figs S1, 2 and 3). These data were confirmed by the decrease of GFAP protein 
expression levels and the increase of Nestin expression, a differentiation and stem markers, respectively (Fig. S1). 
Moreover, CSCs presented a greater ability to form spheres with respect to adherent cells (54.6% CSC, 10.8% 
U87MG, P ≤ 0.001; 39.4% CSC, 9.6% U343MG, P ≤ 0.001; 38.6% CSC, 8.3% T98G, P ≤ 0.001), indicating that 
CSCs retain a clonogenic potential. Finally, different CSCs were confirmed to exhibit a significant higher resist-
ance to TMZ with respect to adherent counterpart (Figs S1E, 2E and 3E). Collectively, these data support the 
reliability of CSC isolation, as we previously reported54.
The effects of CAR on CSC morphology were evaluated by quantifying both the mean area occupied by the 
cells in culture plates and the possible outgrowth of cellular processes. CAR significantly reduced the area occu-
pied by the floating spheres (Fig. 3A,B), without producing outgrowth of cellular processes.
Then, the proliferation rate of CSCs was analyzed. As depicted, CAR induced a time-dependent inhibition of 
U87MG-CSC proliferation (Fig. 3C,D). The effect appeared to be concentration-dependent, with an IC50 value 
of 37.5 ± 5.9 µM after 7 days of treatment (Fig. 3D, Fig. S4A) with a maximum effect of 92.7 ± 3.5%. Similarly, 
CAR was able to decrease the viability of the U343MG-CSCs with an IC50 value of 33.5 ± 2.6 µM after 7 days of 
treatment (Fig. 3E, SI Fig. S4B) but with a maximum effect of only 62.3 ± 1.4%. Conversely, CAR exerted only a 
slight effect on T98G cell viability with a maximum reduction of 22.7 ± 8.2% (Fig. 3E). The different response of 
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Figure 2. Effects of CAR on stemness gene expression and CSC sphere formation. (A) The U87MG cells were 
treated with DMSO (CTRL) or CAR (10 µM) in complete medium for 48 h. At the end of the incubation, a Real 
Time RT-PCR analysis of stem gene expression was performed. The data are presented as the mean values from 
three different experiments each performed in duplicate. (B–E) U87MG cells were incubated with DMSO or 
CAR (10 nM–20 µM) in a defined serum-free NSC medium for 9 days. (B) Representative image. The number 
of the newly formed spheres (C) and the mean diameter (D) were scored using the ImageJ program. The data 
represent the mean values from three pictures from two independent experiments. (E) Cells were treated as 
described above and a Real Time RT-PCR analysis of the stem cell markers or differentiated cell markers was 
performed. The data are presented as the fold of change vs. the expression at basal (day 0) level, before the 
treatment with the NSC medium, and are the mean values from three different experiments. The significance 
of the differences was determined by one-way ANOVA, followed by Bonferroni’s post hoc test: *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001 vs. the CTRL; #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001 vs. 0 day.
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Figure 3. Effects of CAR on the morphology and viability of the CSC. U87MG-derived, U343MG-derived 
and T98G-derived CSCs were treated with complete NSC medium containing DMSO (CTRL) or the indicated 
concentrations of CAR (100 nM-60 µM) for 3 or 7 days. (A) Representative images were captured after 7 days of 
incubation, and the area of the culture plates occupied by the spheres (B) was scored using the ImageJ program. 
The data are presented as the mean values from three independent experiments. For each experimental 
condition, five pictures were analyzed. U87MG-derived CSCs were treated as described above for 3 days (C) or 
7 days (D). Then, cell proliferation was measured using the MTS assay. (E) U343MG-derived and T98G-derived 
CSCs were treated as described above for 7 days. Then, cell proliferation was measured using the MTS assay. 
The data are presented as the mean values from three independent experiments, each performed in duplicate. 
The significance of the differences was determined by one-way ANOVA, followed by Bonferroni’s post hoc test: 
*P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001 vs. the CTRL.
www.nature.com/scientificreports/
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the GBM-CSCs on CAR could be ascribed to the p53 status. CAR inhibition of MDM2/p53 complex confer to the 
diterpene a lower effect on T98G cell that possess a mutated protein, in accordance with the previously reported 
effect of CAR on respective differentiated cells44.
Next, we assessed whether CAR-treated cells could resume growing after the drug was removed. CSCs were 
challenged with CAR (1–60 µM) for 7 days and then washed-out for additional 7 days in drug-free medium. 
The percentages of proliferating cells after the drug removal did not significantly increase, suggesting their 
overall inability to recover normal growth (Fig. 4A). Accordingly, CAR has also been reported to produce a 
long-lasting effect on U87MG cells44. Thus, the diterpene produced long-lasting and anti-proliferative effects on 
the U87MG-derived CSC subpopulation.
To determine if CAR could potentiate the anti-proliferative effect of the alkylating agent temozolomide 
(TMZ), in cancer stem cells, the diterpene and TMZ were combined together. Challenging U87MG-CSCs for 
7 days with TMZ (100–250 µM) plus CAR at different concentrations produced a significant reduction of cell 
proliferation rate (Fig. 4B). These results suggested that CAR enhances TMZ anti-proliferative activity in CSCs, 
in accordance with its effects on adherent U87MG44.
P53 functional reactivation of CAR induced the cell cycle blockade and activated the apoptotic process. Next, 
the mechanisms underlying the reduced CSC proliferation were evaluated. Functional reactivation of p53 has 
been widely correlated to increases in specific p53-related genes57–60. Thus, a real-time RT-PCR analysis of 
the p53-related genes was performed after the U87MG-derived CSC subpopulation were treated with CAR 
Figure 4. CAR sensitize CSCs to TMZ treatment. U87MG-derived CSCs were treated with complete NSC 
medium containing DMSO (CTRL) or the indicated concentrations of CAR (100 nM–60 µM) for 7 days. (A) 
The drug-containing media were replaced with fresh drug-free NSC media and the cells were cultured for an 
additional 7 days. Then, cell proliferation was measured using the MTS assay. (B) U87MG-derived CSCs were 
treated in NSC medium with CAR (1–20 µM) and/or TMZ (100–250 µM) for 7 days. Then, cell proliferation was 
measured using the MTS assay. The data are presented as the mean values from three independent experiments, 
each performed in duplicate. The significance of the differences was determined by one-way ANOVA, followed 
by Bonferroni’s post hoc test: *P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001 vs. the CTRL.
www.nature.com/scientificreports/
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(20–40 µM) for 3 days. CAR was able to significantly increase the mRNA levels of all of the p53 target genes 
(Fig. 5A): p21 (with a maximum increaseof ≈2.1-fold), PUMA (with a maximum increase of ≈1.7-fold), and 
MDM2 (with a maximum increase of ≈2.6-fold). The expression of the pro-apoptotic ‘multi-domain’ Bcl-2 family 
member Bax and the anti-apoptotic protein Bcl-2 was assessed. As expected, CAR treatment caused a significant 
increase in Bax (maximum increase of ≈3.1-fold) and a concomitant decrease in Bcl-2 (maximum decrease of 
≈0.5-fold) (Fig. 5A). The results are in accordance with data showing CAR modulation of p53 levels and the 
functional reactivation of p53-mediated gene transcription in GBM and other cell lines44,61–63.
Challenging CSCs with 10 µM CAR for 7 days did not affect the cell cycle. In contrast, when a higher concen-
tration of CAR was added (20 µM), a decrease in the DNA content in G1/G0 phases and a concomitant increase 
in the number of cells in G2/M phases was observed. Therefore, CAR blocked cell cycle in G2 phase (Fig. 5A,B), 
consistent with previously reported data from U87MG cells44.
The inhibition of MDM2/p53 lead to the functional reactivation of p53 that switch on the apoptotic machin-
ery44. Thus, the CAR apoptotic activity was evaluated (Fig. 5C–E). CAR induced clear, significant signs of 
U87MG-CSC apoptosis after 3 days of treatment, which became more evident after 7 days of incubation (Fig. 5C–
E). Surprisingly, the 3-day treatment with CAR was already sufficient to induce the significant phosphatidylserine 
externalization in the absence of 7-AAD staining, thus denoting the signs of the early phase of apoptosis (Fig. 5C).
Self-renewal of CSCs is reduced by CAR. The main feature of CSCs is their self-renewal capacity9. Herein, 
the effects of CAR on the formation of CSC colonies were evaluated using the soft-agar colony-forming assay 
(Fig. 6A–C). CAR inhibited the colony-forming capacity of CSCs in a dose-dependent manner. CAR signifi-
cantly inhibited the number of newly formed colonies (sphere numbers 14.0 ± 1.1 CAR 20 µM, 40.7 ± 2.4 CTRL, 
P ≤ 0.001; Fig. 6B), highlighting its ability to block the self-renewal of CSCs. Furthermore, CAR decreased the 
mean diameter of the colony in a dose-dependent manner (0.247 ± 0.03 mm2 CTRL, 0.107 ± 0.02 mm2 CAR 
20 µM, P ≤ 0.01; Fig. 6C), thus decreasing the self-renewal rate of CSCs, as well.
A tumor sphere formation assay was performed to deeply assess the ability of CAR to decrease the amount 
of stem cell in neurospheres and limit their self-renewal. CAR, in a dose dependent manner, inhibited the ability 
of CSCs to form spheres (Fig. 6D), as revealed by the decrease in the colony diameter. Furthermore, the CAR 
treatment significantly decreased the efficacy of sphere formation (88.5% CTRL, 33.3% CAR 10 µM, P ≤ 0.001).
Thus, CAR decreased the total number of stem cells and slowed down the self-renewal capacity of the CSCs.
CAR affects stemness signature of U87MG-derived CSCs. Self-renewal capacity is tightly regulated by several 
stem markers64,65. Because CAR modulated the self-renewal properties of CSCs, the effects on stemness gene 
expression were evaluated (Fig. 6E). CAR increased the expression of the differentiation marker GFAP (P ≤ 0.001) 
and decreased the expression of stem cell markers (CD44, Nanog, Oct4, BMI1 and OLIG2). Thus, CAR not only 
affected the viability of CSCs but also could modulate their stemness gene signatures.
Nevertheless, the CSCs in glioblastoma have a greater mesenchymal profile rather than an epithelial one. 
After induction, this phenotype can be shifted toward an even more mesenchymal phenotype in through an 
EMT-like process. Therefore, CSCs were treated with the TNF-α/TGF-β1 mixture, and the expression of EMT 
markers and the transcription factors acting as master regulators was evaluated (Fig. 6F). The mixture caused a 
significant increase in N-cadherin expression (1.68 ± 0.13-fold vs. CTRL, P ≤ 0.05) concomitant with a decrease 
in E-cadherin expression (0.54 ± 0.06-fold vs. CTRL, P ≤ 0.001). The effect on the TFs implicated in the EMT 
was less than the effect observed in U87MG cells. Indeed, only Slug expression was significantly increased after 
treatment with the cytokine mixture compared to the control (1.98 ± 0.08-fold vs. CTRL, P ≤ 0.01). CSCs exposed 
to TNF-α/TGF-β1 only partially underwent the EMT, probably due to the already high expression of stemness 
factors.
CAR did not significantly affect the expression of EMT markers and transcription factors in CSCs in the 
absence of the cytokine mixture. Conversely, CAR (20 µM, a concentration lower the IC50 values on U87MG-CSC 
proliferation) counteracted the EMT elicited by TNF-α/TGF-β1 by reducing the expression of mesenchymal 
markers (Fig. 6F).
In parallel, the intracellular expression of miR-200c, a key negative regulator of the EMT, was also evaluated 
in CSCs. The TNF-α/TGF-β1 mixture significantly decreased miRNA expression (P ≤ 0.01), consistent with the 
data obtained in U87MG cells (Fig. 1F). CAR (20 µM) counteracted the effects of TNF-α/TGF-β1 on miR-200c 
expression (P ≤ 0.01); on the contrary, CAR alone produced only a slight increase in the intracellular miRNA 
levels in the absence of the cytokines.
Thus, CAR was able to interfere with the TNF-α/TGF-β1-induced EMT also in CSC population, despite a 
higher concentration was needed, in accordance with the less sensitiveness of CSCs to chemotherapeutic agents.
Discussion
The natural diterpene CAR, a MDM2/p53 complex inhibitor, decreased the stemness phenotype of human 
U87MG cells by interfering with both the EMT and the stem-like CSC biology. Specifically, CAR affected the 
EMT by decreasing the expression of stemness regulator genes in both U87MG cells and their derived stem-like 
CSCs. In addition, CAR induced CSC apoptosis through the functional reactivation of p53, leading to the reduc-
tion of proliferation and irreversible stem cell death, at least at high concentrations (Fig. 7).
The cancer bulk was principally divided into two cell types consisting of the differentiated cancer cells and the 
undifferentiated CSCs. The glioblastoma-derived CSCs possess self-renewal capacity and are able to differentiate 
into a specular cancer bulk. These cells may be responsible for relapse and metastasis by giving rise to new cancer. 
The acquisition of the mesenchymal phenotype and the presence of CSCs have been widely correlated with an 
increase in cancer aggressiveness in GBM; nevertheless, the link between the EMT, the acquisition of the mesen-
chymal phenotype and the detection of CSCs in the GBM bulk is still unclear9,25–28.
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Recently, our group has reported the anti-proliferative activity of CAR in human GBM cell lines44. CAR inhib-
its the MDM2/p53 complex producing a p53 functional reactivation in adherent U87MG cells44. As reported 
in several recent papers, the oncosuppressor protein, p53, participates in decreasing cancer stemness features, 
Figure 5. CAR effects on the cell cycle progression and apoptosis induction of U87MG-CSCs. U87MG-derived 
CSCs were treated with DMSO (CTRL) or CAR for 3 or 7 days. (A,B) At the end of the treatments, the cell 
cycle was analyzed. The subpopulations of cells in the different phases of the cell cycle are shown. The data are 
presented as the mean values from three different experiments. (C–E) Cells were collected and the amount 
of phosphatidylserine externalization was evaluated using the Annexin V staining protocol. The distribution 
of the live, early and late apoptotic cells. (E) Representative plots are presented. The data are presented as the 
mean values from three different experiments. The significance of the differences was determined by one-way 
ANOVA, followed by Bonferroni’s post hoc test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs. the CTRL; #P ≤ 0.05, 
##P ≤ 0.01, ###P ≤ 0.001 vs. CTRL early apoptotic cells.
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Figure 6. Effects of CAR on the frequency of U87MG sphere-forming cells and self-renewal capacity. (A–C) 
U87MG-derived CSCs were grown in 0.36% agar in NSC medium in the presence of DMSO (0,5%, CTRL) 
or CAR (1–20 µM) for 14 days. At the end of the incubation, representative microscopic images (A) were 
captured at ×4 magnification before and after crystal violet staining. The number (B) and mean area (C) of 
the colonies were scored using the ImageJ program. Only colonies with diameters greater than 60 µm were 
counted. The data are presented as the mean values from three independent experiments. For each experimental 
condition, five pictures were analyzed. (D) A single U87MG-derived CSC was cultured in a 96-well plate and 
maintained in NSC medium for 3 weeks in the absence (CTRL) or presence of different concentrations of CAR 
(100 nM–10 µM). Images were captured at different time points. (E) The U87MG-derived CSCs were treated 
with DMSO (CTRL) or CAR (20) in NSC medium for 7 days. At the end of the incubation, a Real Time RT-PCR 
analysis of the expression of different genes was performed. (F) U87MG-CSCs were treated with TNF-α (10 ng/
ml)/TGF-β1 (10 ng/ml) in the absence or the presence of CAR (20 µM) in NSC medium for 7 days, then a real 
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regulating the CSCs fate66,67, and suppressing the EMT68. Based on the regulatory effect of CAR on p53, the influ-
ence of the diterpene on the EMT, the stemness features of U87MG cells, and CSC viability was evaluated in this 
study.
The tumor inflammatory microenvironment plays a crucial role in facilitating cancer aggressiveness and may 
induce the EMT. As reported by several previous studies, at the molecular level, the EMT is influenced by several 
cytokines, chemokines and growth factors within the inflammatory microenvironment that trigger the expression 
of different stemness genes, favoring the transition to a mesenchymal phenotype13–15,50,69–71. Accordingly, based 
on accumulating evidence, treatments with different factors that induce the EMT lead to an enrichment of cells 
with cancer stem-like features32–34. Although the exact mechanism of the EMT is still unclear, all these aspects are 
related to the aggressiveness of GBM and the escape from a cure.
Herein, a TNF-α/TGF-β mixture was used to induce the peculiar trait of the EMT in U87MG cells. The treat-
ment of U87MG cells with the cytokine mixture increased the levels of several transcription factors identified 
as master regulators of the EMT, including Slug (also known as Snail2), Twist and zinc-finger E-box-binding 
(ZEB1). In parallel, as shown in other solid tumors72–74, the cytokine mixture reduced the expression of the epi-
thelial marker E-cadherin and increased the expression of the mesenchymal marker N-cadherin, consistent with 
the induction of the mesenchymal phenotype.
In adherent U87MG cells, CAR significantly counteracted the TNF-α/TGF-β1 EMT induction. These effects 
may reflect the decrease in U87MG cell migration and the functional reactivation of p53 after the cells were 
exposed to CAR. Indeed, the ability of p53 to reduce metastasis has been widely linked to the negative regulation 
of fundamental factors involved in the initiation and maintenance of the EMT45,75. Notably, CAR was not able to 
perturb the EMT machinery per se, as revealed by the expression of cell surface markers or the expression of tran-
scription factors involved in the EMT. These data are consistent with the effects of CAR on the MDA-231 breast 
cancer cell line43, in which the diterpene did not influence the cell phenotype. Conversely, in the same study, the 
compound reversed the EMT induced by cytokines. In this scenario, CAR not only interferes with CSC features 
by impairing the stem cell phenotype but also decreases the induction of the EMT.
Based on several lines of evidence, different miRNAs, particularly the miR-200 family, play a crucial role in 
regulating the EMT45,76. Among the miR-200 family, the main miRNA involved in cancer progression and the 
EMT is miR-200c. ZEB1, which directly represses the epithelial phenotype, is a well-known and prominent gene 
target of miR-200c77,78. Furthermore, ZEB1 itself negatively regulates miRNA expression in a feed-back loop. 
More interestingly, p53 negatively regulates miR-200c expression. Based on this evidence, we investigated the 
effects of CAR on miR-200c expression. CAR did not directly affect miR-200c or ZEB1 expression, but rather 
counteracted the TNF-α/TGF-β1-induced regulation of miR-200c in U87MG cells. Thus, CAR contributes to 
block the switch to a mesenchymal phenotype induced by the inflammatory microenvironment by reducing the 
aggressive cancer phenotype.The acquisition of stem-like properties is linked to the activation of several genes, 
such as CD44, BMI1, Nanog, Oct4, and SOX2, which are expressed in embryonic stem cells, cancer cells, and 
cancer stem cells. These genes are dysregulated in several cancers, and their modulation may be the basis for 
new, innovative anti-cancer therapies mainly directed toward the cancer stem cell bulk79. CD44 has been widely 
used as a marker for CSCs and it has been implicated in the adhesion, motility, proliferation, and cell survival of 
several cancers. Indeed, CD44 and the B-cell-specific Moloney murine leukemia virus insertion site 1 (BMI1) 
support the stem cell state in both cancer cells and embryonic stem cells. Moreover, the suppression of CD44 
expression has been reported to decrease the formation of tumors and spheres80. The homeobox-containing tran-
scription factor Nanog, the POU domain-containing transcription factor Oct4 and the HMG domain-containing 
transcription factor SOX2 play a crucial role in CSC maintenance81. Herein, the ability of CAR to modulate the 
expression of these stemness genes was demonstrated in both differentiated U87MG cells and more markedly in 
U87MG-derived CSCs. The ability of CAR to interfere with Nanog, Oct4, SOX2, CD44 and BMI1 expression is 
consistent with the effects of other natural compounds (e.g., adriamycin and diflourinated curcumin) to control 
the cancer stem cell bulk and the aggressiveness of glioma and pancreatic adenocarcinoma82,83.
CAR induced a decrease in the expression of the CD44 gene. This effect could be likely related to the inhibi-
tory effect of CAR on MDM2/p53 complex and the increase of intracellular p53 levels. Accordingly, it has been 
demonstrated that p53 regulate stemness by directly repressing CD44 expression75.
BMI1 is overexpressed in various cancers and regulates several intracellular pathways implicated in cell pro-
liferation (p16/Rb and/or p14ARF/MDM2/p53 pathways), invasion (activation of the Akt/GSK3β/Snail pathway) 
and self-renewal (NF-kB-Nanog pathways)84,85. Consistent with the ability of CAR to decrease BMI1 expression, 
the compound also exhibited anti-proliferative effects and reduced invasiveness and self-renewal of the CSCs.
The modulation of EMT master regulators, the control of CSC stem genes and the modulation of miRNA 
expression are correlated with an increase of cancer chemo-sensibility, the reduction of CSC formation and a 
decrease in CSC self-renewal properties86. In previous reports, natural compounds with anti-cancer properties 
were shown to decrease the sphere-forming ability of GBM cell lines87,88. Accordingly, CAR interfered with CSC 
formation by decreasing the expression of stemness markers of glioma CSCs, such as OLIG289. More interestingly, 
CAR decreased the viability of U87MG-derived CSCs by inducing apoptosis, even if it was not able to induce the 
evident differentiation of the stem cells. Finally, CAR also reduced the frequency of stem cells in the sphere and 
Time RT-PCR analysis of the transcription factors (Snail, Slug, Twist and ZEB1) was performed. (G) U87MG 
cells were treated as indicated, and the levels of miR-200c were quantified at the end of the incubation. The data 
are presented as the means of three different experiments. The significance of the differences was determined 
by one-way ANOVA, followed by Bonferroni’s post hoc test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs. the control; 
#P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001 vs. TNF-α/TGF-β1 alone; §§P ≤ 0.01, §§§P ≤ 0.001 vs. CAR alone.
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the self-renewal capacity of CSCs. These findings are consistent with the concomitant decrease in the expression 
of the stem cell genes (SOX2, Oct4 and Nanog). In fact, the expression of SOX2 and Oct4 has been directly linked 
to a higher frequency of sphere-initiating cells in different cancer cell lines90,91. Globally, these data highlighted 
the ability of CAR to interfere with the expression of stemness-related genes, leading to a decrease in stemness 
features accompanied by anti-proliferative effects on human GBM cells with stem-like properties. TMZ is an 
alkylating agent that is used as a first-line chemotherapeutic agent in glioblastoma. Accumulating in vitro and in 
vivo data have shown that different natural compounds enhance the efficacy of chemotherapy and radiotherapy in 
various cancers by regulating different intracellular pathways92. CAR is able to induce apoptosis in chemoresistant 
ovarian cancer cells93 and radiosensitises melanoma cells after radiotherapy94. The ability of CAR to sensitize 
GBM-CSCs cells to TMZ was demonstrated for the first time.
In the discovery of new chemotherapeutic drugs, the safety profile could represents a limitation. The induction 
of apoptosis and the cell cycle blockade could affect the selectivity of anti-tumor agents on cancer cells versus 
non-malignant cells. Notably, it has been reported that the CAR anti-proliferative effects is preferentially directed 
towards cancer cells, as reported in both animal and in vitro models42,95. Furthermore, CAR presented a favoura-
ble therapeutic window in glioblastoma cells as we previously reported44.
Thus, CAR not only affects the viability of differentiated GBM cells, as previously reported, but also interferes 
with the diverse processes implicated in cancer resistance and aggressiveness, such as CSC formation, prolifera-
tion and self-renewal. Interestingly, CAR decreased the influence of the cancer microenvironment by reducing 
the cytokine-induced EMT that underlies the acquisition of the mesenchymal phenotype. Nevertheless other in 
vitro and in vivo studies are fundamental to extend our results and clarify the CAR cellular mechanisms, the CAR 
ability to reactivate the p53 functionality promoting CSC proliferation control and decreasing EMT was high-
lighted for the first time. Thus, we can speculate that the discovery of a compound targeting different features of 
the cancer bulk, which increase its aggressive traits, may represent a promising starting point for the development 
of more effective drugs, particularly for the treatment of cancer with a high grade of complexity and heterogene-
ity, such as GBM.
Materials and Methods
Material. U87MG cells are a human glioblastoma cell line (WHO grade IV) and was purchased from the 
National Institute for Cancer Research of Genoa (Italy). The human T98G and U343MG cell lines (WHO grade 
IV) were obtained from the American Type Culture Collection (USA) and CellLines Service GmbH (Germany), 
respectively. Cell line was controlled for DNA profiling. All other reagents were purchased from commercial 
sources and were of the highest commercially available grade. CAR was purchased by Sigma Aldrich, (Cat. 
C9617).
Cell lines and CSC isolation. U87MG and T98G cells were maintained in RPMI medium supplemented with 
10% FBS, 2 mM L-glutamine, 100 U/mL Penicillin, 100 mg/mL Streptomycin and 1% non-essential amino acids 
(NEAA) at 37 °C in 5% CO2. U343MG cells were maintained in Minimum essential medium Eagle with 2 mM 
Figure 7. Schematic overview of the EMT and CSC connection in the tumor progression and the role of 
CAR in the control of glioblastoma stemness. The tumor microenvironment and extracellular stimuli play 
crucial roles in CSCs formation and EMT transformation. Both these processes are at the basis of the increase 
of glioblastoma stemness and favoring the increase of cancer aggressiveness and recurrence. CAR controls 
the GBM stemness interacting with multiple intracellular pathways decreasing the EMT transition, the CSC 
formation and the CSC maintenance.
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l-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and supplemented with 10% FBS, 100 U/mL penicillin, 
100 mg/mL streptomycin, 1% non-essential amino acids and 1.0 mM sodium pyruvate at 37 °C in 5% CO2.
The isolation of derived CSCs was performed as previously described96. Briefly, approximately 2.5 × 106 cells 
were suspended in 1 mL of serum-free Neural Stem Cell (NSC) medium. After 3–5 days of culture, the CSCs 
(called “neurospheres”) were collected, suspended in NSC medium and plated for the assays. The derived-CSCs 
was characterized as previously reported96,97. For the long-term treatment of cells, NSC or complete medium 
containing drugs was replaced every two to three days.
mRNA extraction and Real Time RT-PCR analysis. U87MG cells (3.5 × 103 cell/cm2) and derived-CSC 
cells (40 spheres/500 µl) were treated with DMSO (CTRL) or CAR (at the reported concentrations) in the absence 
or the presence of Tumors necrosis factor α (TNF-α, 10 ng/ml) and Trasforming growth factor β1 (TGF-β, 10 ng/
ml) for indicated times. Then, cells were collected, and total RNA was extracted using Rneasy® Mini Kit (Qiagen) 
according to manufacturer’s instructions. 500 ng of RNA were transformed in cDNA using i-Script cDNA syn-
thesis kit (BioRad, Hercules, USA) following manufacturer’s instructions. Real-time RT-PCR reactions mix con-
sisted of: 25 µL Fluocycle® II SYBR® (Euroclone), 1.5 µL of both 10 µM forward and reverse primers, 3 µL cDNA, 
and 19 µL of H2O. Reactions were performed for 40 cycles using this temperature profiles: 98 °C for 30 seconds 
(initial denaturation); Tann (Table 1) for 30 seconds (annealing); and 72 °C for 3 seconds (extension). Primer used 
were reported in Table 198. β-actin was used as the housekeeping gene. The mRNA levels for each sample were 
Gene Primer nucleotide sequences
Product size 
(base pairs)
Annealing 
Temperature
CD44 FOR: 5′-CCGCTATGTCCAGAAAGGA-3′ REV: 5′-CTGTCTGTGCTGTCGGTGAT-3′ 195 bp 55 °C
CD133 FOR: 5′-TCCACAGAAATTTACCTACATTGG -3′ REV: 5′CAGCAGTTCAAGACGCAGATGACCA-3′ 251 bp 61 °C
Nanog FOR: 5′-CATGAGTGTGGATCCAGCTTG-3′ REV: 5′-CCTGAATAAGCAGATCCATGG-3′ 192 bp 55 °C
Oct4 FOR: 5′-CTCACCCTGGGGGTTCTATT-3′ REV: 5′-CTCCAGGTTGCCTCTCACTC-3′ 230 bp 55 °C
BMI1 FOR: 5′-CCTGATGTGTGTGCTTTGTGG-3′ REV: 5′-TCATTAGAGCCATTGGCAGCA-3′ 291 bp 55 °C
SOX2 FOR: 5′-CATGAAGGAGCACCCGGATT-3′ REV: 5′-ATGTGCGCGTAACTGTCCAT-3′ 186 bp 55 °C
Nestin FOR: 5′-CAGCGTTGGAACAGAGGTTGG-3′ REV: 5′-TGGCACAGGTGTCTCAAGGG-3′ 282 bp 61 °C
OLIG2 FOR: 5′-CAGAAGCGCTGATGGTCATA-3′ REV: 5′-TCGGCAGTTTTGGGTTATTC-3′ 208 bp 55 °C
GFAP FOR: 5′-GCTCCGGAGACCCCTTCCA-3′ REV: 5′-GACAACCGCCACTCAACTAGC-3′ 287 bp 52 °C
STAT3 FOR: 5′-GGCATTCGGGAAGTATTGTCG-3′ REV: 5′-GGTAGGCGCCTCAGTCGTATC-3′ 318 bp 55 °C
N-Cad FOR: 5′-AGGGGACCTTTTCCTCAAGA-3′ REV: 5′-CAATGTCAATGGGGTTCTCC-3′ 246 bp 55 °C
E-Cad FOR: 5′-AGGGGTTAAGCACAACAGCA-3′ REV: 5′-GGGGGCTTCATTCACATCCA-3′ 395 bp 55 °C
Snail FOR: 5′-AAGATGCACATCCGAAGCCA-3′ REV: 5′-CATTCGGGAGAAGGTCCGAG-3′ 237 bp 55 °C
Slug FOR: 5′-TGGTTGCTTCAAGGACACAT-3′ REV: 5′-GTTGCAGTGAGGGCAAGAA-3′ 66 bp 55 °C
Twist FOR: 5′-ACGAGCTGGACTCCAAGATG-3′ REV: 5′-CACGCCCTGTTTCTTTGAAT-3′ 290 bp 55 °C
ZEB1 FOR: 5′-CCCTTGAAAGTGATCCAGCCA-3′ REV: 5′-AGACCCAGAGTGTGAGAAGCG-3′ 354 bp 55 °C
MDM2 FOR: 5′-TCTAGGAGATTTGTTTGGCGT-3′ REV: 5′-TCACAGATGTACCTGAGTCC-3′ 125 bp 55 °C
p21 FOR: 5′-TGCCGAAGTCAGTTCCTTG -3′ REV: 5′-CATGGGTTCTGACGGACATC-3′ 134 bp 55 °C
BAX FOR: 5′-TTTGCTTCAGGGTTTCATCC-3′ REV: 5′-CAGTTGAAGTTGCCGTCAGA-3′ 245 bp 55 °C
PUMA FOR: 5′-GAGGAGGAACAGTGGGC-3′ REV: 5′- CTAATTGGGCTCCATCTCGG-3′ 198 bp 55 °C
p53 FOR: 5′-CTTTGAGGTGCGTGTTTGTG-3′ REV: 5′-GTGGTTTCTTCTTTGGCTGG-3′ 161 bp 55 °C
Bcl-2 FOR: 5′-GAGGATTGTGGCCTTCTTTG-3′ REV: 5′-ACAGTTCCACAAAGGCATCC-3′ 171 bp 55 °C
β-actin FOR: 5′-GCACTCTTCCAGCCTTCCTTCC-3′ REV: 5′-GAGCCGCCGATCCACACG-3′ 254 bp 55 °C
Table 1. Primers Used for Real-Time RT-PCR.
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normalized against β-actin mRNA levels, and relative expression was calculated by using Ct value. The melting 
curve analysis and gel electrophoresis were performed to test the PCR specificity.
Western blotting analysis of EMT markers expression. U87MG cells (3.5 × 103 cell/cm2) were treated 
with DMSO (CTRL) or with CAR (10 µM) for 48 h, and then 200 μl RIPA buffer were added for 60 min at 4 °C to 
lyse the cells. 50 μg of total proteins was diluted in Laemmli solution, resolved by SDS-PAGE (7.5%), transferred to 
PVDF membranes and probed overnight at 4 °C with primary anti-E-cadherin antibody (diluted 1:200; sc-7870; 
Santa Cruz Biotechnology) or anti-N-cadherin antibody (diluted 1:200; sc-7939; Santa Cruz Biotechnology) or 
β-actin antibody (diluted 1:1000; MAB1501, Merck KGaA, Darmstadt, Germany). The primary antibody was 
detected using anti-rabbit IgG light chains conjugated to peroxidase (diluted 1:10000; 12–348; Millipore). The 
peroxidase was detected using a chemioluminescent substrate (ECL, Perkin Elmer), and the images were acquired 
by photographic film or by LAS4010 (GE Health Care Europe, Uppsala, Sweden). Immunoreactive bands were 
quantified performing a densitometric analysis with Image J Software.
miRNA quantification analysis. miRNA was extracted from U87MG or derived-CSCs, treated as indi-
cated, using the miRNeasy Mini Kit (Qiagen, Valencia, CA) following the manufacturer’s protocol. The expression 
of miRNAs was quantified using Taqman real-time reverse transcription RT–PCR assays following the manufac-
turer’s protocol (Applied Biosystems, Foster city, CA). In brief, 20 ng of total RNA was reverse transcribed and 
6 ng of complementary DNA was used in each well for real-time RT–PCR. Each PCR reaction was performed in 
duplicate or triplicate. The quantification was performed using RNU6B Assay ID 001093 and hsa-miR-200c Assay 
ID 002300 (Applied Biosystems, Foster city, CA). The RNU6B was used as reference. The miRNA levels for each 
sample were normalized against RNU6B levels, and relative expression was calculated by using Ct value.
Neurosphere formation assay. The ability of U87MG cells monolayer to initiate neurosphere formation 
was assessed as previously described96. Briefly, U87MG cells were seeded in 96 well plate at a density of 2 × 104 
cells/well in serum-free NSC medium and incubated with DMSO (0.5%, CTRL) or CAR (10 nM–20 μM) for 
9 days without disturbing the plates and without replenishing the medium. At the end of the incubation time, 
images of the neurospheres were taken. Three wells were analysed and three images of each well were captured. 
The number and the mean diameter of the newly formed neurospheres were counted using the ImageJ program 
(version 1.41; Bethesda, MD, USA).
CSC viability and quantification of neurosphere area. The U87MG-derived, U343MG-derived and 
T98G-derived CSCs were seeded (40 spheres/well) and treated with different CAR concentrations (1–40 µM) 
alone or in the presence of TMZ (100–250 µM) for 7 days. Then, cell proliferation was evaluated using the MTS 
assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay kit; Promega) according to manufacturer’s 
instruction. The absorbance at 490 nm was measured with an automated plate reader (Victor Wallac 2, Perkin 
Elmer). For wash-out experiments, CSCs were treated with CAR (1–40 µM) for 7 days. Then, medium-containing 
drugs was replaced by fresh medium, and cells were allowed to growth for additional 7 days. Finally, MTS 
assay were performed to assess the cell proliferation in accordance to the manufacture instructions. Sigmoid 
dose-response curves were generated using GraphPad 5.0, from which the IC50 values were derived. Analysis of 
the neurosphere areas was performed as previously described96. Briefly, photographs of the neurospheres were 
taken at days 7. Three different wells were analysed for each condition, and 10 images of each well were captured. 
The area occupied by neurospheres that had formed was quantified using the ImageJ program.
CSCs apoptosis and cell cycle analyses. For apoptosis measurement, CSCs were treated with DMSO 
(CTRL) or CAR for 7 days. Then, the percentages of living, apoptotic and dead cells were quantified and analysed 
by Muse™ Cell Analyzer (Merck KGaA, Darmstadt, Germany)96. The live, early apoptotic and late apoptotic/dead 
cells were discriminated using the staining with Annexin V and 7-Aminoactinomycin D (7-AAD).
For the cell cycle analysis, CSCs were treated with DMSO (CTRL) or CAR for 7 days. The quantification of the 
percentage of cells in the different cell phases was performed using the Muse™ Cell Analyzer96.
Self-renewal assessment. Clonogenic and soft-agar colony forming assays were performed. For the clonal 
dilution assay, CSCs were dissociated and seeded at dilutions of 1 cell/well in NSC medium. Wells that contained 
a single cell were identified with microscopic observation, and the cells were maintained in NSC medium in the 
absences (CTRL) or presence of CAR (100 nM–10 µM). After 7, 14, or 21 days, colony formation was scored. The 
percentage of cells that formed spheres was determined by the following equation: (Y(n)/X(n)) *100 where X(n) 
is the number of wells in which a single cell was present and Y(n) is the number of wells in which one neurosphere 
developed from a single cell. The mean percentage of wells containing one neurosphere was measured and the 
mean diameter was evaluated using ImageJ program.
For the soft-agar colony formation assay, CSCs were dissociated, and 500 µl of 1 × 103 cells in NSC medium 
containing 0.3% agar (low melting temperature agarose, Sigma-Aldrich) was plated on a layer of 500 µl of the 
same medium containing 0.6% agar in a 24 well plate. The plates were fed weekly with 0.2 ml of NSC medium. 
Two weeks after plating, the colonies were stained with 0.005% crystal violet, and photographs of the stained 
colonies were taken. The image were analysed using ImageJ program.
Statistical analysis. The Graph-Pad Prism program (GraphPad Software Inc., San Diego, CA) was used 
for data analysis and graphic presentation. All data are the mean ± SEM of at least three different experiments. 
Statistical analysis was performed by one-way analysis of variance (ANOVA) with Bonferroni’s corrected t-test 
for post-hoc pair-wise comparisons. P < 0.05 was considered statistically significant.
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